1-9 of 9
Candice Jamois
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

Martin Hutchings, Michael J. Dickinson, Giuseppe Gritti, Carmelo Carlo-Stella, William Townsend, Francesc Bosch, Nancy L. Bartlett, Guillaume Cartron, Herve Ghesquieres, Roch Houot, Harriet S. Walter, Fritz Offner, Natalie Dimier, Candice Jamois, Lance Smith, Sylvia Herter, Denis Sahin, Abiraj Keelara, Koorosh Korfi, Jeremy Gallien, Marie-Helene Wasmer, Heather Hinton, Matt Whayman, Isabel Prieto, Georgios Kazantzidis, Katharina Lechner, Franck Morschhauser
Journal: Blood
Blood (2024) 144 (Supplement 1): 990.
https://doi.org/10.1182/blood-2024-200096
Published: 2024
Journal Articles

CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

Koorosh Korfi, Sabine Wilson, Zhiwen Jiang, Ailsa Christiansen, Sreenath Krishnan, Candice Jamois, Annika Blank, Alexandra Epp, Abraham Silva, Philip Knuckles, Joanne Hayward, Johannes Sam, Katharina Lechner, Natalie Dimier, Paolo F. Caimi, Lorenzo Falchi, Giuseppe Gritti, Franck Morschhauser, Martin Hutchings, Michael J. Dickinson, Carmelo Carlo-Stella
Journal: Blood
Blood (2024) 144 (Supplement 1): 644.
https://doi.org/10.1182/blood-2024-201406
Published: 2024
Journal Articles

Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients

Candice Jamois, Koorosh Korfi, Sylvia Herter, Sabine Wilson, Sreenath Krishnan, Marie-Helene Wasmer, Isabel Prieto, Heather Hinton, Wouter Driessen, Georgios Kazantzidis, Denis Sahin, Akiko Tagawa, Natalie Dimier, Katharina Lechner
Journal: Blood
Blood (2024) 144 (Supplement 1): 4180.
https://doi.org/10.1182/blood-2024-201466
Published: 2024
Journal Articles

BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL

Michael J. Dickinson, Martin Hutchings, Franck Morschhauser, Carmelo Carlo-Stella, Lorenzo Falchi, Paolo F. Caimi, Natalie Dimier, Lance Smith, Matt Whayman, Johannes Sam, Abiraj Keelara, Koorosh Korfi, Candice Jamois, Jeremy Gallien, Nicole Martin, Iris Martinez Quetglas, Heather Hinton, Isabel Prieto, Francesca Michielin, Katharina Lechner, Giuseppe Gritti
Journal: Blood
Blood (2024) 144 (Supplement 1): 3123.
https://doi.org/10.1182/blood-2024-205544
Published: 2024
Journal Articles

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy

Johannes Sam, Thomas Hofer, Christine Kuettel, Christina Claus, Jenny Thom, Sylvia Herter, Guy Georges, Koorosh Korfi, Martin Lechmann, Miro Julian Eigenmann, Daniel Marbach, Candice Jamois, Katharina Lechner, Sreenath M. Krishnan, Brenda Gaillard, Joana Marinho, Sven Kronenberg, Leo Kunz, Sabine Wilson, Stefanie Briner, Samuel Gebhardt, Ahmet Varol, Birte Appelt, Valeria Nicolini, Dario Speziale, Miriam Bez, Esther Bommer, Jan Eckmann, Carina Hage, Florian Limani, Silvia Jenni, Anne Schoenle, Marine Le Clech, Jean-Baptiste Pierre Vallier, Sara Colombetti, Marina Bacac, Stephan Gasser, Christian Klein, Pablo Umaña
Journal: Blood
Blood (2024) 143 (21): 2152–2165.
https://doi.org/10.1182/blood.2023023381
Published: 2024
Includes: Supplemental data
Journal Articles

New Tocilizumab (TCZ) Dosing Guidance for T-Cell Engaging Bispecific Antibody-Related Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Insights from Pooled Clinical Trial Safety Experience and Quantitative Clinical Pharmacology (qCP) Analyses

Candice Jamois, David C. Turner, Leonid Gibiansky, Feifei Li, Nicolas Frey, Jean-Francois Menuet, Leonardo Roque Pereira, Linda Lundberg, Elena Guerini, David John Carlile, James Relf, Michael C. Wei, Antonia Kwan, Susan Grange
Journal: Blood
Blood (2023) 142 (Supplement 1): 1742.
https://doi.org/10.1182/blood-2023-177679
Published: 2023
Journal Articles

Contribution of Idasanutlin Exposure to Safety, Pharmacodynamics and Clinical Response of Patients with Acute Myeloid Leukemia Treated with Idasanutlin + Cytarabine in Phase I and III Studies

Candice Jamois, PharmD, Doreen Anders, Benjamin M. Beckermann, PhD, Magali Genevray, MD, Kirsten Mundt, PhD, Claire Petry, Joy Yang, Nastya Kassir, Christophe Schmitt
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-136419
Published: 2020
Journal Articles

Greater Efficacy and Potency of Obinutuzumab Compared with Rituximab in Chronic Lymphocytic Leukemia Patients Confirmed By a Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Model

Kubra Kamisoglu, Alex Phipps, Candice Jamois, Vincent Buchheit, Georgina Meneses-Lorente, Günter Fingerle-Rowson, Jonathan Wagg, Donald E Mager
Journal: Blood
Blood (2017) 130 (Supplement 1): 1267.
https://doi.org/10.1182/blood.V130.Suppl_1.1267.1267
Published: 2017
Journal Articles

Influence of Baseline Disease Characteristics and Exposure to Obinutuzumab on Clinical Outcome in Patients with Previously Untreated Advanced Follicular Lymphoma Treated with Obinutuzumab-Based Immunochemotherapy in the GALLIUM Trial

Candice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, Vincent Buchheit, Pauline Baumlin, Denis Sahin, Guillaume Cartron, Robert Marcus, Wolfgang Hiddemann, MD PhD, John F Seymour, MBBS, PhD, Jonathan C Strefford, PhD, Georgina Meneses-Lorente, Nicolas Frey, Günter Fingerle-Rowson
Journal: Blood
Blood (2017) 130 (Supplement 1): 3848.
https://doi.org/10.1182/blood.V130.Suppl_1.3848.3848
Published: 2017